The Journal of Urology
Volume 181, Issue 1 , Pages 354-362 , January 2009

PTEN Knockout Prostate Cancer as a Model for Experimental Immunotherapy

  • Kazunori Haga

      Affiliations

    • Department of Medicine, University of California-Los Angeles, California
    • Equal study contribution.
    • ,
  • Atsushi Tomioka

      Affiliations

    • Department of Medicine, University of California-Los Angeles, California
    • Department of Urology, Nara Medical University, Nara, Japan
    • Equal study contribution.
    • ,
  • Chun-Peng Liao

      Affiliations

    • Departments of Pathology, and Biochemistry and Molecular Biology, University of Southern California, Los Angeles, California
    • ,
  • Takahiro Kimura

      Affiliations

    • Department of Medicine, University of California-Los Angeles, California
    • Department of Urology, Jikei Medical University, Tokyo, Japan
    • ,
  • Hiroshi Matsumoto

      Affiliations

    • Department of Medicine, University of California-Los Angeles, California
    • ,
  • Izumi Ohno

      Affiliations

    • Department of Medicine, University of California-Los Angeles, California
    • ,
  • Kip Hermann

      Affiliations

    • Department of Medicine, University of California-Los Angeles, California
    • ,
  • Christopher R. Logg

      Affiliations

    • Department of Medicine, University of California-Los Angeles, California
    • ,
  • Jing Jiao

      Affiliations

    • Department of Molecular and Medical Pharmacology, University of California-Los Angeles, California
    • ,
  • Motoyoshi Tanaka

      Affiliations

    • Department of Urology, Kinki University, Osaka, Japan
    • ,
  • Yoshihiko Hirao

      Affiliations

    • Department of Urology, Nara Medical University, Nara, Japan
    • ,
  • Hong Wu

      Affiliations

    • Department of Medicine, University of California-Los Angeles, California
    • Department of Molecular and Medical Pharmacology, University of California-Los Angeles, California
    • ,
  • Carol A. Kruse

      Affiliations

    • Sidney Kimmel Cancer Center, San Diego, California
    • ,
  • Pradip Roy-Burman

      Affiliations

    • Departments of Pathology, and Biochemistry and Molecular Biology, University of Southern California, Los Angeles, California
    • ,
  • Noriyuki Kasahara

      Affiliations

    • Department of Medicine, University of California-Los Angeles, California
    • Department of Molecular and Medical Pharmacology, University of California-Los Angeles, California
    • Corresponding Author InformationCorrespondence and requests for reprints: Department of Medicine, University of California-Los Angeles, 675 Charles E. Young Dr. South, MRL-1551, Los Angeles, California 90095 (telephone: 310-825-7112; FAX: 310-825-5204)

Received 2 April 2008

References 

  1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10
  2. McNeel DG. Prostate cancer immunotherapy. Curr Opin Urol. 2007;17:175
  3. Kruse CA, Rubinstein D. Cytotoxic T lymphocytes reactive to patient major histocompatibility proteins for therapy of recurrent primary brain tumors. In:  Liau LM,  Becker DP,  Cloughsey TF,  Bigner DD editor. Brain Tumor Immunotherapy. New York: Humana Press; 2001;p. 149–170
  4. Buhler P, Wolf P, Gierschner D, Schaber I, Katzenwadel A, Schultze-Seemann W, et al. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Cancer Immunol Immunother. 2008;57:43
  5. Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res. 2005;65:9080
  6. Pinthus JH, Waks T, Kaufman-Francis K, Schindler DG, Harmelin A, Kanety H, et al. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res. 2003;63:2470
  7. Young JG, Green NK, Mautner V, Searle PF, Young LS, James ND. Combining gene and immunotherapy for prostate cancer. Prostate Cancer Prostatic Dis. 2007;
  8. Zhang Q, Yang X, Pins M, Javonovic B, Kuzel T, Kim SJ, et al. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res. 2005;65:1761
  9. Anderson MJ, Shafer-Weaver K, Greenberg NM, Hurwitz AA. Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J Immunol. 2007;178:1268
  10. Roy-Burman P, Wu H, Powell WC, Hagenkord J, Cohen MB. Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr Relat Cancer. 2004;11:225
  11. Tennant TR, Kim H, Sokoloff M, Rinker-Schaeffer CW. The Dunning model. Prostate. 2000;43:295
  12. Goebel HW, Rausch U, Steinhoff M, Seitz J, Bacher M, Papotti M, et al. Arguments against the prostatic origin of the R-3327 Dunning H tumor. Virchows Arch B Cell Pathol Incl Mol Pathol. 1992;62:9
  13. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95:29
  14. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 1997;57:4997
  15. Mulholland DJ, Dedhar S, Wu H, Nelson CC. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene. 2006;25:329
  16. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell. 2003;4:209
  17. Jiao J, Wang S, Qiao R, Vivanco I, Watson PA, Sawyers CL, et al. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res. 2007;67:6083
  18. Bhaumik S, Gambhir SS. Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc Natl Acad Sci U S A. 2002;99:377
  19. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989;24:148
  20. Hiraoka K, Kimura T, Logg CR, Kasahara N. Tumor-selective gene expression in a hepatic metastasis model after locoregional delivery of a replication-competent retrovirus vector. Clin Cancer Res. 2006;12:7108
  21. Brakenhielm E, Burton JB, Johnson M, Chavarria N, Morizono K, Chen I, et al. Modulating metastasis by a lymphangiogenic switch in prostate cancer. Int J Cancer. 2007;121:2153
  22. Liao CP, Zhong C, Saribekyan G, Bading J, Park R, Conti PS, et al. Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res. 2007;67:7525
  23. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982;155:1063
  24. Gomez GG, Hutchison RB, Kruse CA. Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer. Cancer Treat Rev. 2001;27:375
  25. Kruse CA, Mitchell DH, Kleinschmidt-DeMasters BK, Bellgrau D, Eule JM, Parra JR, et al. Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma. J Neurooncol. 1993;15:97
  26. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346
  27. Rosenberg SA, Yang JC, Robbins PF, Wunderlich JR, Hwu P, Sherry RM, et al. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother. 2003;26:385

 Study received approval from University of California-Los Angeles and University of Southern California (Project No. 2003-120-12).

 Supported by National Institutes of Health Grants R01 CA121258 (NK), R01 CA059705 and R01 CA113392 (PRB), Idea Award PC074133 (NK and PRB) and Post-Doctoral Training Award PC073547 (KH) from the Department of Defense Prostate Cancer Research Program, and Developmental Research Program seed grant from the University of California-Los Angeles Specialized Program of Research Excellence in Prostate Cancer (NK).

PII: S0022-5347(08)02416-6

doi: 10.1016/j.juro.2008.08.124

The Journal of Urology
Volume 181, Issue 1 , Pages 354-362 , January 2009

Article Tools

* Image Usage & Resolution